Physician profile
Charles E Brodowski
NPI 1114489721
$3,512.87
in general payments reported to CMS, 2019-2025
17 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $28.64 · 2021: $71.99 · 2022: $138 · 2023: $1,326 · 2024: $1,060 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,172.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,212.30 | 2022-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Acrysof Iq Vivity |
| Sight Sciences, INC. | $964.70 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $549.39 | 2023-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $151.64 | 2023-2025 | Vyzulta, Miebo |
| New World Medical,INC. | $144.08 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $102.45 | 2019 | |
| Horizon Therapeutics Plc | $100.00 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $59.53 | 2023-2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $43.94 | 2025 | Acthar |
| Amgen INC. | $38.01 | 2025 | Tepezza |
| E.R. Squibb & Sons, L.L.C. | $28.64 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $26.19 | 2023 | |
| Biotissue Holdings INC. | $21.55 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $21.46 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $18.48 | 2025 | Tyrvaya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17.42 | 2024 | Vabysmo |
| Abbvie INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Brodowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.